Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: The US Preventive Services Task Force (USPSTF) includes multitarget stool DNA (mt-sDNA) testing as a colorectal cancer (CRC) screening option in average-risk individuals, but data on colonoscopy outcomes after positive mt-sDNA tests in community settings are needed.
Aim: The aim of this study was to investigate colonoscopy outcomes and quality following positive mt-sDNA in the population-based New Hampshire Colonoscopy Registry.
Methods: We compared colonoscopy outcomes and quality between age-matched, sex-matched, and risk-matched patients from 30 endoscopy practices with and without a preceding positive mt-sDNA test. Main outcomes were colonoscopy findings of CRC, advanced noncancerous neoplasia, nonadvanced neoplasia, or normal examination. Quality measures included withdrawal time, bowel preparation quality, examination completion, and percentage of average-risk individuals with normal colonoscopies receiving a USPSTF-recommended 10 year rescreening interval.
Results: Individuals with positive mt-sDNA tests (N=306, average age 67.0 y; 61.8% female) were significantly more likely than colonoscopy-only patients (N=918, 66.2 y; 61.8% female) to have CRC (1.3% vs. 0.4%) or advanced noncancerous neoplasia (27.1% vs. 8.2%) (P<0.0001). Neoplasia was found in 68.0% of patients having colonoscopy after a positive mt-sDNA test, (positive predictive value, was 68.0%), versus 42.3% of patients with colonoscopy only (P<0.0001). No significant differences in colonoscopy quality measures were observed between cohorts.
Conclusions: Colonoscopy after a positive mt-sDNA test was more frequently associated with CRC and colorectal neoplasia than colonoscopy alone. Positive mt-sDNA tests can enrich the proportion of colonoscopies with clinically relevant findings. Follow-up recommendations suggest that endoscopists do not inappropriately shorten rescreening intervals in mt-sDNA-positive patients with normal colonoscopy. These findings support the clinical utility of mt-sDNA for CRC screening in community practice.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/MCG.0000000000001554 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Anatomical location of colorectal neoplasia in patients with positive stool tests (mt-sDNA or FIT): Data from the New Hampshire Colonoscopy Registry.
Gastrointest Endosc
September 2025
Geisel School of Medicine at Dartmouth, Hanover, NH; Department of Medicine, Section of Gastroenterology and Hepatology, Dartmouth-Hitchcock Medical Center, Lebanon, NH; NH Colonoscopy Registry, Lebanon, NH.
Background And Aims: Data comparing the location of polyp yield in patients with positive stool tests can aid screening test selection. We conducted a cross sectional analysis of New Hampshire Colonoscopy Registry data to compare the location, left versus right side of the colon, of neoplasia detected on colonoscopy following a mt-sDNA+ or FIT+ test as compared to a reference group having colonoscopy without a stool test.
Methods: Our outcomes were advanced lesions (adenoma and/or serrated polyp, including cancer), advanced adenomas (AA), or advanced serrated polyps (ASP), stratified by location.
Adherence to Follow-Up Colonoscopy After a Positive Stool-Based Test in Patients Aged 45-49 Years: Real-World Differences Between Multitarget Stool DNA Testing and Fecal Immunochemical or Fecal Occult Blood Testing.
Gastro Hep Adv
May 2025
Exact Sciences Corporation, Madison, Wisconsin.
Background And Aims: A positive stool-based test (SBT) result requires timely follow-up colonoscopy (FU-CY) to realize the full benefits of screening recommendations. The current investigation examined the real-world rate of, and time to, FU-CY adherence among patients aged 45-49 years who were screened with either a fecal immunochemical test (FIT)/fecal occult blood test (FOBT) or a multitarget stool DNA test (mt-sDNA).
Methods: This retrospective study utilized a large integrated national multipayer claims database.
Improving CRC screening in an underserved population: real-world adherence to mt-sDNA testing among the incarcerated in Nebraska, United States.
Curr Med Res Opin
May 2025
Nebraska Department of Correctional Services, Lincoln, NE, USA.
Objectives: This study assessed adherence to colorectal cancer (CRC) screening with a multi-target stool DNA (mt-sDNA) test in a real-world, carceral setting.
Methods: This was a retrospective observational study in a prison system using laboratory data from Exact Sciences Laboratories LLC. Individuals aged 45-85 years incarcerated by the Nebraska Department of Correctional Services (Nebraska, United States) covered under a single National Provider Identifier were included.
Effects of Oral Anticoagulant and Antiplatelet Agents on Performance of Multitarget Colorectal Cancer Screening Test.
Gastro Hep Adv
January 2025
Gastroenterology, Mayo Clinic Health System - Northwest Wisconsin region, Eau Claire, Wisconsin.
Background And Aims: The multitarget stool DNA (mt-sDNA) test is a noninvasive screening tool for colorectal cancer. We aimed to clarify the effects of antiplatelet and anticoagulant medications on the diagnostic performance of this test.
Methods: We retrospectively identified patients undergoing mt-sDNA testing from Mayo Clinic sites across the US during a 5-year period.
The Utility of Multitarget Stool DNA Testing in Community-Based Clinical Practice.
Am J Gastroenterol
April 2025
Division of Gastroenterology, Palmetto Primary Care Physicians, Summerville, South Carolina, USA .
Introduction: Multitarget stool DNA (MT-sDNA) tests (i.e., Cologuard) serve as screening tests for colorectal cancer (CRC) and are recommended by the US Preventive Services Task Force every 1-3 years.
View Article and Find Full Text PDF